Erratum to: Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study

Erratum to: Osteoporos Int

DOI 10.1007/s00198-014-2756-8

In the second paragraph of the Introduction section, the last portion of the first sentence states: “… and approved for use for the treatment of osteoporosis in Japan [11].” This was inadequately referenced, and should be “approved for use for the treatment of osteoporosis in Japan [11, 17–19].”

In the fourth paragraph of the Discussion section, the first portion of the first sentence states: “While many reports have indicated the bone density-increasing effects of switching to daily minodronate from other BPs [11, 17–19], …” This was incorrectly referenced, and should be “While many reports have indicated the bone density-increasing effects of switching to daily minodronate from other BPs [23–25], …”

In the fifth paragraph of the Discussion section, the first portion of the first sentence states: “While daily minodronate has been reported to alleviate low back pain [19], …”. Additionally, in the sixth paragraph of the Discussion section, the first sentence states: “We have already reported that daily minodronate treatment induced fewer GI symptoms in comparison with weekly alendronate treatment [19].” The reference number [19] is incorrect and should be [18] in both cases.

An inappropriate publication was cited as reference 21. The correct reference is:

21. Nozaki K, Kakimoto S, Kimoto A, Yoshino T, Sato Y, Yoshida A, Nakamura T (2011) Investigation into the analgesic effects of minodronic acid hydrate via P2X_2/3 receptor (in Japanese). Shinyaku To Rinsho (J New Rem Clin) 60(9):1766–1774

The following three publications should have been included in the References section.

23. Shimoda J (2010) Clinical experience with minodronate for the treatment of osteoporosis unresponsive to alendronate therapy (in Japanese). Osteoporosis Jpn 18(4):739–744

24. Kogawa R, Takagi H (2011) Clinical efficacy of minodronic acid hydrate, a newly developed bisphosphonate, in osteoporotic patients who responded poorly to alendronate therapy (in Japanese). Osteoporosis Jpn 19(4):725–734

25. Matsui H (2012) Clinical effects of minodronic acid hydrate in patients with postmenopausal osteoporosis who underwent first bisphosphonate therapy or pretreatment with risedronate (in Japanese). Central Japan Association of Orthopaedic Surgery & Traumatology 55(3):531–532